

## REMARKS / ARGUMENTS

### Restriction Requirement

Claims 1-20 were pending. The Examiner has required restriction of the claims to one of the following groups under 35 U.S.C. §121:

- I. Claims 1-14 and 16-17, drawn to a method for treating a LFA-1 mediated disorder in a mammal comprising administering an initial dosing of an anti-ICAM-1 antibody, classified in Class 424, subclass 152.1 and 172.1.
- II. Claims 1-18 and 20, drawn to a method for treating a LFA-1-mediated disorder in a mammal comprising administering an initial dosing of an anti-CD18 antibody, classified in Class 424, subclass 152.1 and 172.1.
- III. Claims 1-20, drawn to a method for treating a LFA-1-mediated disorder in a mammal comprising administering an initial dosing of an anti-CD11a antibody, classified in Class 424, subclass 152.1 and 172.1.

Applicants elect without traverse to prosecute the invention of Group III. However, the claims have been amended to specify multiple sclerosis as the LFA-1-mediated disorder and LFA-1 antagonist as anti-CD11a antibody.

### **Amendments to the specification and claims**

The specification has been amended to correct typographical errors and to insert the trademark symbols where necessary.

By virtue of this amendment, claims 6, 7, 9, 11, 15, 17, 18, 19 and 20 are canceled without prejudice to refiling continuing application(s) directed thereto, claims 21-24 are added and claims 1-5, 13-14, and 16 are amended. Upon entry of this amendment, claims 1-5, 8, 10, 12-14, and 16, and 21-24 will be pending.

In view of the restriction requirement, claim 1 has been amended to recite anti-CD11a antibody as supported, e.g., in claim 19. Amended claim 1 recites treatment of multiple

Appl. no. 10/727,383  
Amdt. dated 10/20/2004  
Reply to Office action of 05/20/2004

sclerosis, a disorder disclosed in the specification on at least page 11, line 24. Furthermore, claim 1 now specifies that "the antibody is administered to the mammal not more than once per week during the subsequent intermittent dosing" which finds specification basis on at least page 22, lines 10-11 and in original claim 13. Claims 2-5 clarify that the percentages disclosed therein are "calculated on a daily basis", which is supported in claim 1 and on page 21, lines 20-30, for example. Claims 2-5 have also been amended to refer to "antibody", in view of the amendment to base claim 1. Claims 13, 14 and 16 have been amended to correct claim dependency and to provide proper antecedent basis upon the amendment of claim 1 and the cancellation of certain claims.

New claims 21-24 are supported in the specification, for example, on page 33, lines 3-13; page 34, line 33 to page 35, line 4, and in Fig. 5; page 14 last line through page 15, line 2; and on page 22 in the second paragraph. No new matter has been introduced by these amendments and their entry is respectfully requested.

If a telephone interview would be of assistance in advancing prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided below.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 07-0630 (Ref. Docket No. P790C4D1C2).

Respectfully submitted,  
GENENTECH, INC.

Date: October 20, 2004

By: Lee K. Tan  
Lee K. Tan, Ph.D.  
Reg. No. 39,447  
Telephone: (650)225-4462

document# 157509